<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700645</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-18-YA-354-18-CTIL</org_study_id>
    <nct_id>NCT03700645</nct_id>
  </id_info>
  <brief_title>Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease</brief_title>
  <official_title>Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerosis is a progressive disease of the arterial wall, arising from the combination
      of endothelial dysfunction and inflammation. This link is exacerbated in diabetic patients.

      Uric acid is known to generate oxidative stress and it's elevated levels has been shown to be
      associated with cardiac hypertrophy, inflammation, myocardial fibrosis and diastolic
      dysfunction. Allopurinol inhibits xanthine oxidase, an enzyme that regulates uric acid
      production. In observational studies it has been shown to reduce ischemia, inflammation and
      improve coronary flow. The aim of this study is to see whether treatment with Allopurinol in
      patients diagnosed with multivessel disease and undergoing treatment with either percutaneous
      coronary intervention (PCI) or coronary artery bypass surgery (CABG) , will reduce markers of
      inflammation and improve quality of life and major adverse cardiovascular effects (MACE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study, PROBE design (prospective randomized open label blinded endpoints
      study), that will include 100 patients.

      Patients will be recruited during their hospitalization in the cardiology department of
      Ichilov- Tel-Aviv Sourasky Medical Center.

      It will include patients with known or newly diagnosed diabetes mellitus, hospitalized with
      diagnosis of acute coronary syndrome and multi-vessel coronary artery disease (CAD) that will
      be demonstrated by cardiac catheterization that the patients will undergo during their
      hospitalization in concordance with their diagnosis and practice guidelines.

      The decision about intervention with either PCI or CABG will be accepted by a heart team
      after the initial demonstration of multi-vessel disease.

      Study recruitment will take place either in the first 24 hours after PCI or before CABG.

      All patients will sign an informed consent and randomized before any intervention is done.

      After enrollment, patients will undergo the following baseline procedure (no later than 24
      hours from PCI):

        1. Physical examination and medical interview

        2. Quality of life questionnaires (Seattle angina , EQ-5D)

        3. Echocardiogram

        4. Blood tests- see below for description

        5. Endothelial function using the EndoPatÂ®

      Blood sampling will be done via IV cannula that will be placed in an antecubital vein. Blood
      sample analyses will be performed using reagents, calibrators and control materials in the
      local labs of each participating site. A 40 ml blood sample will be obtained for the
      following blood tests

        1. Full chemistry including: lipid levels, thyroid function, liver enzymes function,
           Troponin, BNP, HbA1c, uric acid, creatinine and glucose levels.

        2. Blood count

        3. Inflammatory biomarker (hs-CRP, fibrinogen, IL-6, IL-1B, IL-18, MMP, IL-10, IL-35, TNFa,
           AchE , PAI-1, MPO, cholinergic status.)

        4. Endothelial function markers: Endothelin-1, I-CAM, V-CAM, superoxide dismutase ADMA, and
           oxidized LDL

        5. Oxidative Stress- superoxide dismutase ADMA, and oxidized LDL, Plasma protein carbonyls.

        6. Urine samples- microalbuminuria, albumin/creatinine. Uric acid.

      Endothelial function will be assessed using EndoPAT 2000 device (Itamar Medical Inc.,
      Caesarea, Israel) that is a device that measures endothelial function using a sensor placed
      on the fingers. This device has been validated and used previously to assess peripheral
      arterial tone in other populations. EndoPAT bio-sensors are placed on the index fingers of
      both arms. EndoPAT quantifies the endothelium-mediated changes in vascular tone, elicited by
      a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the
      cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated
      Dilatation (FMD). The dilatation, manifested as reactive hyperemia, is captured by EndoPAT as
      an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is
      calculated by the EndoPAT software, providing the EndoPAT index. In addition, the EndoPAT
      system will measure heart rate variability.

      After randomization and assessment as described above, the patients will receive treatment
      according to the study arm they were assigned to which will include either standard medical
      therapy alone, or standard medical therapy and allopurinol.

      Allopurinol will be given initially at 100 mg once daily dose, with dose escalation by 100 mg
      every 2 weeks till final dose of 300 mg daily will be reached.

      After discharge, patients will be assessed several times:

        1. One month after in cardiology clinic. Assessment will include all the tests as in the
           pre study exam (see above). also, patients will be monitored for the possible side
           effects of allopurinol treatment.

        2. Three months- in cardiology clinic. Assessment will include all the tests as in the pre
           study exam (see above).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>3 months.</time_frame>
    <description>Change in inflammatory biomarkers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>one month</time_frame>
    <description>Change in inflammatory biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function markers</measure>
    <time_frame>3 month</time_frame>
    <description>Endothelin-1, I-CAM, V-CAM, superoxide dismutase ADMA, and oxidized LDL, Change of RH-PAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>3 month</time_frame>
    <description>Heart rate variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional status and quality of life: the Seattle angina questionnaire</measure>
    <time_frame>3 month</time_frame>
    <description>Quality of life evaluation- evaluates functional limitation in different activities due to chest pain and angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid levels</measure>
    <time_frame>one month and 3 month</time_frame>
    <description>Uric acid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional status, quality of life: EuroQol EQ-5D questionnaire</measure>
    <time_frame>3 month</time_frame>
    <description>evaluation of degree of limitation in different daily activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of peri-procedural myocardial infarction</measure>
    <time_frame>72 hours</time_frame>
    <description>Reduction of peri-procedural myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>3 month</time_frame>
    <description>major adverse cardiac events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function</measure>
    <time_frame>3 month</time_frame>
    <description>Diastolic function per echocardiogram- E/A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function</measure>
    <time_frame>3 month</time_frame>
    <description>Diastolic function per echocardiogram-E/E' med</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function</measure>
    <time_frame>3 month</time_frame>
    <description>Diastolic function per echocardiogram- E/E' lat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function</measure>
    <time_frame>3 month</time_frame>
    <description>Diastolic function per echocardiogram- DT time</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Ischemic Heart Disease</condition>
  <condition>Multi Vessel Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PCI and standard medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and receive standard medical treatment according to practice guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCI, standard treatment and Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and in addition to standard medical treatment, receive treatment with allopurinol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG and standard medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and receive standard medical treatment according to practice guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG standard treatment and Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and in addition to standard medical treatment, receive treatment with allopurinol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol</description>
    <arm_group_label>CABG standard treatment and Allopurinol</arm_group_label>
    <arm_group_label>PCI, standard treatment and Allopurinol</arm_group_label>
    <other_name>Alloril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute Coronary Syndrome with positive troponin

          2. Patients with known or newly diagnosed diabetes mellitus with HbA1c above 7% and below
             10%

          3. Patients above the age of 40

          4. Stable Hemodynamic state (At least 12 hours from presentation with acute coronary
             syndrome)

          5. Uric Acid &gt; 6mg/dl or 355 micromol/l (males) and &gt;5mg/dl or 297 Micromol/l (females)

        Exclusion Criteria:

          1. HbA1c below 7% or above 10%

          2. Severe valvular insufficiency/Stenosis

          3. Major surgery within 30 days

          4. Any medical condition that would impair participation (e.g. progressive neurological
             disorders, mental illness)

          5. Known intolerance/ current use of allopurinol/colchicine

          6. Chronic inflammatory diseases: e.g. Lupus, rheumatoid arthritis, etc.

          7. Current treatment with steroids, NSAID, chemotherapy or biologic medications

          8. Extra-cardiac illness that is expected to limit survival to less than 2 years.

          9. Past Cancer within the past 5 years (excluding BCC and SCC).

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron Arbel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalia Kofman, M.D</last_name>
    <phone>97239673222</phone>
    <email>natalia.kofman@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaron Arbel, M.D</last_name>
    <phone>97236973222</phone>
    <email>yarona@tlvmc.gov.il</email>
  </overall_contact_backup>
  <reference>
    <citation>Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26. Review.</citation>
    <PMID>9887164</PMID>
  </reference>
  <reference>
    <citation>Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39. doi: 10.1056/NEJMoa0808431. Epub 2008 Dec 17. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1028. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1024-5.</citation>
    <PMID>19092145</PMID>
  </reference>
  <reference>
    <citation>ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.</citation>
    <PMID>21366473</PMID>
  </reference>
  <reference>
    <citation>BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796. Epub 2009 Jun 7.</citation>
    <PMID>19502645</PMID>
  </reference>
  <reference>
    <citation>Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11;369(2):145-54. doi: 10.1056/NEJMoa1212914. Epub 2013 Jun 24. Erratum in: N Engl J Med. 2014 May 8;370(19):1866.</citation>
    <PMID>23796131</PMID>
  </reference>
  <reference>
    <citation>Arbel Y, Zlotnik M, Halkin A, Havakuk O, Berliner S, Herz I, Rabinovich I, Keren G, Bazan S, Finkelstein A, Banai S. Admission glucose, fasting glucose, HbA1c levels and the SYNTAX score in non-diabetic patients undergoing coronary angiography. Clin Res Cardiol. 2014 Mar;103(3):223-7. doi: 10.1007/s00392-013-0641-7. Epub 2013 Nov 24.</citation>
    <PMID>24271460</PMID>
  </reference>
  <reference>
    <citation>de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, Oemrawsingh RM, Akkerhuis KM, Boersma E. Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med. 2013 Nov 11;173(20):1896-904. doi: 10.1001/jamainternmed.2013.10074.</citation>
    <PMID>24018647</PMID>
  </reference>
  <reference>
    <citation>Yang SW, Zhou YJ, Tian XF, Pan GZ, Liu YY, Zhang J, Guo ZF, Chen SY, Gao ST, Du J, Jia DA, Fang Z, Hu B, Han HY, Gao F, Hu DY, Xu YY; Beijing Heart and Metabolism Survey Study Group. Association of dysglycemia and all-cause mortality across the spectrum of coronary artery disease. Mayo Clin Proc. 2013 Sep;88(9):930-41. doi: 10.1016/j.mayocp.2013.05.022.</citation>
    <PMID>24001485</PMID>
  </reference>
  <reference>
    <citation>Neogi T, George J, Rekhraj S, Struthers AD, Choi H, Terkeltaub RA. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 2012 Feb;64(2):327-38. doi: 10.1002/art.33369. Review.</citation>
    <PMID>21953377</PMID>
  </reference>
  <reference>
    <citation>Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014 Nov;10(11):654-61. doi: 10.1038/nrrheum.2014.124. Epub 2014 Aug 19. Review.</citation>
    <PMID>25136785</PMID>
  </reference>
  <reference>
    <citation>Jia G, Habibi J, Bostick BP, Ma L, DeMarco VG, Aroor AR, Hayden MR, Whaley-Connell AT, Sowers JR. Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. Hypertension. 2015 Mar;65(3):531-9. doi: 10.1161/HYPERTENSIONAHA.114.04737. Epub 2014 Dec 8.</citation>
    <PMID>25489061</PMID>
  </reference>
  <reference>
    <citation>Baena CP, Lotufo PA, Mill JG, Cunha Rde S, BenseÃ±or IJ. Serum Uric Acid and Pulse Wave Velocity Among Healthy Adults: Baseline Data From the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Am J Hypertens. 2015 Aug;28(8):966-70. doi: 10.1093/ajh/hpu298. Epub 2015 Jan 21.</citation>
    <PMID>25609603</PMID>
  </reference>
  <reference>
    <citation>Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol. 2012 May;59(3):235-42. doi: 10.1016/j.jjcc.2012.01.013. Epub 2012 Mar 6. Review.</citation>
    <PMID>22398104</PMID>
  </reference>
  <reference>
    <citation>Gotsman I, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail. 2012 Sep;18(9):694-701. doi: 10.1016/j.cardfail.2012.06.528. Epub 2012 Aug 3.</citation>
    <PMID>22939038</PMID>
  </reference>
  <reference>
    <citation>Miyaoka T, Mochizuki T, Takei T, Tsuchiya K, Nitta K. Serum uric acid levels and long-term outcomes in chronic kidney disease. Heart Vessels. 2014 Jul;29(4):504-12. doi: 10.1007/s00380-013-0396-0. Epub 2013 Aug 9.</citation>
    <PMID>23929090</PMID>
  </reference>
  <reference>
    <citation>Wu AH, Ghali JK, Neuberg GW, O'Connor CM, Carson PE, Levy WC. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J. 2010 Nov;160(5):928-33. doi: 10.1016/j.ahj.2010.08.006.</citation>
    <PMID>21095282</PMID>
  </reference>
  <reference>
    <citation>Ito H, Abe M, Mifune M, Oshikiri K, Antoku S, Takeuchi Y, Togane M. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One. 2011;6(11):e27817. doi: 10.1371/journal.pone.0027817. Epub 2011 Nov 18.</citation>
    <PMID>22125626</PMID>
  </reference>
  <reference>
    <citation>Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012 May 31;157(2):255-7. doi: 10.1016/j.ijcard.2012.01.092. Epub 2012 Feb 21.</citation>
    <PMID>22360949</PMID>
  </reference>
  <reference>
    <citation>Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013 Jun;99(11):759-66. doi: 10.1136/heartjnl-2012-302535. Epub 2013 Jan 23. Review.</citation>
    <PMID>23343689</PMID>
  </reference>
  <reference>
    <citation>Fan Y, Wei F, Lang Y, Wang S. Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. J Hypertens. 2015 Apr;33(4):681-8; discussion 689. doi: 10.1097/HJH.0000000000000478.</citation>
    <PMID>25915869</PMID>
  </reference>
  <reference>
    <citation>El-Bassossy HM, Watson ML. Xanthine oxidase inhibition alleviates the cardiac complications of insulin resistance: effect on low grade inflammation and the angiotensin system. J Transl Med. 2015 Mar 6;13:82. doi: 10.1186/s12967-015-0445-9.</citation>
    <PMID>25889404</PMID>
  </reference>
  <reference>
    <citation>Erdogan D, Tayyar S, Uysal BA, Icli A, Karabacak M, Ozaydin M, Dogan A. Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2012 Nov-Dec;28(6):721-7. doi: 10.1016/j.cjca.2012.04.005. Epub 2012 Jun 19.</citation>
    <PMID>22717250</PMID>
  </reference>
  <reference>
    <citation>Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, Lang CC, George J, Struthers AD. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013 Mar 5;61(9):926-32. doi: 10.1016/j.jacc.2012.09.066.</citation>
    <PMID>23449426</PMID>
  </reference>
  <reference>
    <citation>Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010 Aug 9;170(15):1358-64. doi: 10.1001/archinternmed.2010.198.</citation>
    <PMID>20696962</PMID>
  </reference>
  <reference>
    <citation>de Abajo FJ, Gil MJ, RodrÃ­guez A, GarcÃ­a-Poza P, Ãlvarez A, Bryant V, GarcÃ­a-RodrÃ­guez LA. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart. 2015 May;101(9):679-85. doi: 10.1136/heartjnl-2014-306670. Epub 2015 Jan 5.</citation>
    <PMID>25561685</PMID>
  </reference>
  <reference>
    <citation>Grimaldi-Bensouda L, AlpÃ©rovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P; PGRx MI Group. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015 May;74(5):836-42. doi: 10.1136/annrheumdis-2012-202972. Epub 2014 Jan 6.</citation>
    <PMID>24395556</PMID>
  </reference>
  <reference>
    <citation>Struthers A, Shearer F. Allopurinol: novel indications in cardiovascular disease. Heart. 2012 Nov;98(21):1543-5. doi: 10.1136/heartjnl-2012-302249. Epub 2012 Jul 16.</citation>
    <PMID>22801998</PMID>
  </reference>
  <reference>
    <citation>Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010 Nov 19;145(2):257-258. doi: 10.1016/j.ijcard.2009.08.037. Epub 2009 Sep 22.</citation>
    <PMID>19775763</PMID>
  </reference>
  <reference>
    <citation>Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19;131(20):1763-71. doi: 10.1161/CIRCULATIONAHA.114.014536. Epub 2015 Apr 14.</citation>
    <PMID>25986447</PMID>
  </reference>
  <reference>
    <citation>Higgins P, Walters MR, Murray HM, McArthur K, McConnachie A, Lees KR, Dawson J. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Heart. 2014 Jul;100(14):1085-92. doi: 10.1136/heartjnl-2014-305683. Epub 2014 May 1.</citation>
    <PMID>24790069</PMID>
  </reference>
  <reference>
    <citation>Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011 Jul;22(7):1382-9. doi: 10.1681/ASN.2010111185. Epub 2011 Jun 30.</citation>
    <PMID>21719783</PMID>
  </reference>
  <reference>
    <citation>Erol T, Tekin A, KatÄ±rcÄ±baÅÄ± MT, Sezgin N, Bilgi M, Tekin G, ZÃ¼mrÃ¼tdal A, Sezgin AT, MÃ¼derrisoÄlu H. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol. 2013 Aug 20;167(4):1396-9. doi: 10.1016/j.ijcard.2012.04.068. Epub 2012 May 8.</citation>
    <PMID>22572633</PMID>
  </reference>
  <reference>
    <citation>Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, PÃ©rez de Jose A, CedeÃ±o S, Linares T, LuÃ±o J. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015 Apr;65(4):543-9. doi: 10.1053/j.ajkd.2014.11.016. Epub 2015 Jan 13.</citation>
    <PMID>25595565</PMID>
  </reference>
  <reference>
    <citation>Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010 Jun 19;375(9732):2161-7. doi: 10.1016/S0140-6736(10)60391-1. Epub 2010 Jun 9.</citation>
    <PMID>20542554</PMID>
  </reference>
  <reference>
    <citation>Guedes M, EsperanÃ§a A, Pereira AC, Rego C. What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol? An evidence-based review. Rev Port Cardiol. 2014 Nov;33(11):727-32. doi: 10.1016/j.repc.2014.06.002. Epub 2014 Nov 20. Review. English, Portuguese.</citation>
    <PMID>25444231</PMID>
  </reference>
  <reference>
    <citation>Castrejon I, Toledano E, Rosario MP, Loza E, PÃ©rez-Ruiz F, Carmona L. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int. 2015 Jul;35(7):1127-37. doi: 10.1007/s00296-014-3189-6. Epub 2014 Dec 18. Review. Erratum in: Rheumatol Int. 2015 Jul;35(7):1139.</citation>
    <PMID>25519877</PMID>
  </reference>
  <reference>
    <citation>Kydd AS, Seth R, Buchbinder R, Falzon L, Edwards CJ, van der Heijde DM, Bombardier C. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl. 2014 Sep;92:33-41. doi: 10.3899/jrheum.140460. Review.</citation>
    <PMID>25180126</PMID>
  </reference>
  <reference>
    <citation>Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014 Oct 14;(10):CD006077. doi: 10.1002/14651858.CD006077.pub3. Review.</citation>
    <PMID>25314636</PMID>
  </reference>
  <reference>
    <citation>Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015 Oct;26(10):2155-61. doi: 10.1093/annonc/mdv317. Epub 2015 Jul 27.</citation>
    <PMID>26216382</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>Director. Research &amp; development, Tel-Aviv Sourasky Medical Center</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Uric asid</keyword>
  <keyword>Multi Vessel Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

